Therefore, our conclusion that CD200 MFI < 189.5 predicted shorter TTT in CLL may be not applicable to other laboratories, and they should have their own CD200 MFI cutoff to predict the outcome of CLL patients although a training set might be needed to determine the cutoff value. This evidence concerns the gene CD200 and B-cell chronic lymphocytic leukemia.